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Abstract 
Background: Although depression is a common comorbidity of chronic obstructive pulmonary disease (COPD), the 
role of sex remains unexplored. We evaluated sex differences of risk factors of depressive symptoms in adults with 
COPD.
Methods: This was a population‑based cross‑sectional study using data from the 2014 and 2016 Korea National 
Health and Nutrition Examination Survey. Spirometry was used to identify patients with COPD, defined as a  FEV1/FVC 
ratio < 0.7. Presence of depressive symptoms was defined as a total score ≥ 5 on the Patient Health Questionnaire‑9.
Results: 17.8% of participants expressed depressive symptoms. Relative regression analysis revealed that female 
sex (RR 2.38; 95% CI 1.55–3.66; p < 0.001), living alone (RR 1.46; 95% CI 1.08–1.97; p = 0.013), current smoker (RR 1.70; 
95% CI 1.15–2.52; p = 0.008), underweight (RR 1.58 95% CI 1.00–2.49; p = 0.049), and GOLD Stage III/IV (RR 1.92; 95% 
CI 1.19–3.09; p = 0.007) were the risk factors for depressive symptoms. Low income, living alone, multiple chronic 
disorders, and low BMI were risk factors of depressive symptoms in male, whereas low educational attainment, urban 
living, and current smoking were risk factors in female.
Conclusions: Female sex is a main risk factor of depressive symptoms in adults with COPD. As risk factors of depres‑
sive symptoms in COPD patients vary according to their sex, different approaches are needed to manage depression 
in males and females with COPD.
Keywords: Depressive symptoms, Chronic obstructive pulmonary disease, Sex, Korea National Health and Nutrition 
Examination Survey (KNHANES)
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Background
Chronic obstructive pulmonary disease (COPD) is char-
acterized by airflow limitation resulting from airway 
inflammation and remodeling that is not fully reversible 
[1]. Patients with COPD frequently present with several 
comorbidities, including hypertension, cardiovascular 
disease, diabetes mellitus, osteoporosis, and lung cancer 
[2–5]. Depression is considered one of the most com-
mon comorbidities of COPD, with estimates of depres-
sion prevalence in COPD ranging from 10 to 57% [6]. 
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Although depression in patients with COPD is related to 
a poor quality of life, more frequent exacerbations, and 
increase in mortality [5, 7, 8], previous studies reported 
that only 27–33% of those with depression were being 
treated for it [5, 9]. Untreated depressive symptoms may 
increase physical disability, morbidity, and healthcare 
utilization, while early identification of these psychiatric 
conditions and subsequent psychological intervention in 
patients with COPD might improve the clinical outcomes 
[7].
Previous studies have reported risk factors for depres-
sion in patients with COPD, including living alone, severe 
COPD, impaired physical functioning [10, 11]. However, 
studies on how the risk factors of depressive symptoms 
in COPD patients differ according to sex are insufficient. 
Therefore, the aim of this study was to identify that sex 
is a risk factor of depressive symptoms in patients with 
COPD. Furthermore, the secondary objective was to 
explore whether the risk factors of depressive symptoms 
were different in COPD patients according to sex.
Methods
Survey overview
The study data were obtained from the Korea National 
Health and Nutrition Examination Survey (KNHANES), 
a nationally representative population-based cross-sec-
tional survey that evaluates the health and nutritional 
status of the Korean population conducted annually by 
the Centers for Disease Control and Prevention in Korea. 
The survey collected detailed information on demo-
graphic, socioeconomic, and clinical characteristics, 
including age, educational attainment, economic activity, 
household income, marital status, alcohol consumption, 
smoking habits, and previous and current diseases.
Survey participants were selected from 192 regions in 
Korea based on a stratified multistage sampling method. 
The survey was composed of several components, includ-
ing a health behavior questionnaire, health interview, 
health examination, and nutritional survey. Participants 
aged over 40  years also performed a spirometry test 
using a spirometer as part of the health examination. 
The KNHANES 2014 and 2016 surveys included the 
Patient Health Questionnaire-9 (PHQ-9), which is a self-
reported depression screening scale. Therefore, we used 
survey data from these two years. The KNHANES pro-
vides secondary data that is publicly available and a more 
detailed description of the survey profile can be found 
elsewhere [12].
Study population
This study initially assessed data from 6329 eligible par-
ticipants with valid lung function measurements. After 
excluding participants who did not meet the COPD 
criteria, and those with any missing variables, including 
PHQ-9 score, a total of 877 participants were included 
in the final analysis (Fig. 1).
Assessment of lung function
Lung function was measured by trained medical tech-
nicians according to the manual of the American Tho-
racic Society/European Respiratory Society Task Force, 
using dry rolling seal spirometers (Model 2130; Sen-
sor Medics, Yorba Linda, CA, USA) [13]. The forced 
expiratory volume in 1  s (FEV1), forced vital capacity 
(FVC), and FEV1/FVC ratio were obtained. COPD was 
defined as a pre-bronchodilator FEV1/FVC ratio below 
0.7, according to 2018 Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines [14]. 
The severity of COPD (GOLD Stage) was classified 
based on the percent-predicted FEV1: Stage I (mild; 
FEV1 ≥ 80%), Stage II (moderate; FEV1 50–79%), Stage 
III (severe; FEV1 30–49%), and Stage IV (very severe; 
FEV1 < 30%).
Fig. 1 Flow diagram of the study participants. FEV1, forced expiratory 
volume in 1 s; FVC, forced vital capacity; KNHANES, Korea National 
Health and Nutritional Examination Survey; PHQ‑9, Patient Health 
Questionnaire‑9
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Assessment of body mass index and depressive symptoms
Body mass index (BMI) was calculated as weight/
height squared (kg/m2) and classified into: underweight 
(BMI < 18.5), normal (18.5 ≤ BMI < 23), overweight 
(23 ≤ BMI < 25), and obese (BMI ≥ 25) according to the 
revised Asia–Pacific BMI criteria by the World Health 
Organization Western Pacific Region [15].
Depressive symptoms were assessed using the PHQ-9, 
a nine-item self-reported questionnaire [16]. The ques-
tionnaire is based on the criteria of the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition, 
which is used to diagnose several specific types of depres-
sive disorders [17]. Each item on the PHQ-9 is scored on 
a scale from 0 to 3. The scores are then summed as a total 
score ranging between 0 and 27. PHQ-9 total scores of 5, 
10, 15, and 20 represent valid thresholds of mild, mod-
erate, moderately severe, and severe depression, respec-
tively. PHQ-9 is in the public domain and the scale can 
be used free of charge [18]. Following previous studies 
on depressive symptoms using KNHANES data [19–21], 
the presence of depressive symptoms was defined as a 
PHQ-9 ≥ 5 in this study [22]. All participants were cat-
egorized into two groups depending on whether they had 
depressive symptoms according to this cut-off score.
Assessment of covariates
We included socio-demographic variables: sex, age, edu-
cational attainment, equalized household income, liv-
ing status, economic activity, and residential area. Age 
groups were divided into five categories as 40–49, 50–59, 
60–69, 70–79, and 80 or older. Educational attainment 
was categorized as ‘elementary school or below,’ ‘mid-
dle school graduate,’ ‘high school graduate,’ or ‘college 
or above.’ Equalized household income was categorized 
into quartiles from ‘quartile 1 (low income)’ to ‘quartile 
4 (high income).’ Living status was categorized as ‘living 
alone’ or ‘living together.’ Economic activity was catego-
rized as ‘employed’ or ‘unemployed.’ Residential area was 
categorized as ‘urban’ or ‘rural.’
We also included health-related variables as additional 
potential confounders: alcohol consumption status, 
smoking status, chronic medical diseases, and GOLD 
Stage. Alcohol consumption and smoking status were 
categorized as ‘never use,’ ‘former use,’ or ‘current use.’ 
Chronic medical diseases, including hypertension, dia-
betes mellitus, angina, myocardial infarction, and stroke, 
were collected via self-reported doctor diagnosis. The 
total number of diseases was summed and classified into 
three groups as ‘zero,’ ‘one,’ and ‘two or more.’ For anal-
yses, GOLD Stages III and IV were combined into one, 
resulting in three categories, ‘Stage I,’ ‘Stage II,’ and ‘Stage 
III/IV.’
Statistical analysis
All data are presented as numbers and percentages. 
Categorical comparisons were performed using the chi-
square test. Multivariable analysis was performed using 
the relative risk regression analysis with prespecified 
covariates. Relative risk (RR) and 95% confidence inter-
vals (CIs) were also calculated. A p-value < 0.05 was 
considered significant for all analyses. Data analyses 
were performed using SAS software, version 9.4 (SAS 
Institute, Cary, NC, USA).
Ethical approval
The research protocol was approved by the Institutional 
Review Board (IRB) of Severance Hospital. The need 
for informed consent was waived by the IRB of Sever-
ance Hospital as the data were de-identified in the data-
base used (IRB number: 4–2019-0854).
Results
Baseline characteristics of the study participants
A total of 877 COPD participants were identified during 
the study period (Table 1), with a mean age at diagnosis 
of 66.1 years (SD 9.5) and a proportion of 71.5% males. 
Among these patients, 156 patients reported depressive 
symptoms, with an incidence of 17.8% (156/877).
There was a higher proportion of females among 
those who’ve reported depressive symptoms in com-
parison to those without depressive symptoms. Low 
educational attainment, low household income, current 
smoking, underweight, and GOLD Stage III/IV were 
also found to be associated with depressive symptoms. 
Detailed description is available in Table 1.
Factors associated with depressive symptoms
Table  2 shows the results of relative risk regression 
analysis for the associated factors with depressive 
symptoms. According to the adjusted multiple regres-
sion analysis, the following variables were associated 
with depressive symptoms; female sex (RR 2.38; 95% 
CI 1.55–3.66; p < 0.001), living alone (RR 1.46; 95% CI 
1.08–1.97; p = 0.013), current smoker (RR 1.70; 95% 
CI 1.15–2.52; p = 0.008), underweight (RR 1.58 95% CI 
1.00–2.49; p = 0.049), and GOLD Stage III/IV (RR 1.92; 
95% CI 1.19–3.09; p = 0.007). Furthermore, there was a 
43% reduction in the incidence of depressive symptoms 
(RR 0.57; 97.5% CI 0.33–0.97; P = 0.039) among high 
household income participants.
Sex differences in the factors associated with depressive 
symptoms
Multivariable relative regression analysis was used to 
compare sex stratified models that estimated the RRs 
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Table 1 Characteristics of the study participants
With depressive symptoms 
(PHQ-9 ≥ 5)
Without depressive symptoms 
(PHQ-9 < 5)
Total participants P value
(N = 156) (N = 721) (N = 877)
Sex < 0.001
Male 82 (52.6) 545 (75.6) 627 (71.5)
Female 74 (47.4) 176 (24.4) 250 (28.5)
Age (years, mean ± SD) 67.2 ± 9.5 65.9 ± 9.5 66.1 ± 9.5 0.125
Age (years) 0.336
40–49 9 (5.8) 54 (7.5) 63 (7.2)
50–59 22 (14.1) 118 (16.4) 140 (16.0)
60–69 50 (32.0) 259 (35.9) 309 (35.2)
≥ 70 75 (48.1) 290 (40.2) 365 (41.6)
Educational attainment < 0.001
Elementary school or below 82 (52.6) 255 (35.4) 337 (38.4)
Middle school 23 (14.7) 140 (19.4) 163 (18.6)
High school 33 (21.2) 194 (26.9) 227 (25.9)
College or above 18 (11.5) 132 (18.3) 150 (17.1)
Equalized household income < 0.001
Quartile 1 (low) 79 (50.6) 215 (29.8) 294 (33.5)
Quartile 2 37 (23.7) 206 (28.6) 243 (27.7)
Quartile 3 21 (13.5) 142 (19.7) 163 (18.6)
Quartile 4 (high) 19 (12.2) 158 (21.9) 177 (20.2)
Living status < 0.001
Living together 102 (65.4) 614 (85.2) 716 (81.6)
Living alone 54 (34.6) 107 (14.8) 161 (18.4)
Economic activity 0.006
Employed 65 (41.7) 390 (54.1) 455 (51.9)
Unemployed 91 (58.3) 331 (45.9) 422 (48.1)
Residential area 0.176
Urban 69 (44.2) 274 (38.0) 343 (39.1)
Rural 87 (55.8) 447 (62.0) 534 (60.9)
Alcohol consumption status 0.037
Never drinker 26 (16.7) 95 (13.2) 121 (13.8)
Former drinker 62 (39.7) 230 (31.9) 292 (33.3)
Current drinker 68 (43.6) 396 (54.9) 464 (52.9)
Smoking status < 0.001
Never smoker 69 (44.3) 234 (32.5) 303 (34.6)
Former smoker 40 (25.6) 310 (43.0) 350 (39.9)
Current smoker 47 (30.1) 177 (24.5) 224 (25.5)
Chronic medical diseases 0.465
None 76 (48.7) 364 (50.5) 440 (50.2)
One 50 (32.1) 247 (34.2) 297 (33.9)
Two or more 30 (19.2) 110 (15.3) 140 (15.9)
BMI (kg/m2, mean ± SD) 23.3 ± 3.3 24.0 ± 2.9 23.8 ± 3.0 0.024
BMI < 0.001
Underweight 12 (7.7) 14 (1.9) 26 (3.0)
Normal weight 62 (39.7) 258 (35.8) 320 (36.5)
Overweight 34 (21.8) 198 (27.5) 232 (26.4)
Obesity 48 (30.8) 251 (34.8) 299 (34.1)
GOLD stage 0.019
Stage 1 75 (48.1) 373 (51.7) 448 (51.1)
Stage 2 67 (43.0) 321 (44.5) 388 (44.2)
Stage 3 and 4 14 (8.9) 27 (3.8) 41 (4.7)
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of depressive symptoms (Table  3). Male with lower 
household income, living alone (RR 1.97; 95% CI 
1.18–3.28; p = 0.009), with the presence of two or more 
chronic medical diseases (RR 2.04; 95% CI 1.15–3.63; 
p = 0.015), and low BMI (RR 3.35; 95% CI 1.16–9.68; 
p = 0.026) showed association with depressive symp-
toms. For females, low educational attainment, living 
in urban, and current smoking were significant factors 
associated with depressive symptoms. Detailed descrip-
tion is available in Table 3.
Discussion
In this study, we investigated the prevalence and risk fac-
tors of depressive symptoms in adults with COPD, find-
ing that the incidence of depressive symptoms was 17.8% 
(156/877). Female sexwas a main risk factor of depres-
sive symptoms in adults with COPD. Additionally, lower 
BMI, living alone, being a current smoker, and having a 
high severity of COPD (GOLD Stage III/IV) were signifi-
cant risk factors of depressive symptoms. Furthermore, 
we found that the risk factors of depressive symptoms 
in COPD patients were different with respect to sex. In 
males, low BMI, low income, living alone, and combined 
chronic medical disease were related with the occurrence 
of depressive symptoms, whereas low educational attain-
ment, living in an urban setting, and being a current 
smoker were risk factors in females.
Depression is common in patients with chronic disease, 
including COPD, heart disease, stroke, and diabetes, and 
screening and providing interventions for depression 
early should be emphasized to prevent worsening of the 
disease [23]. In COPD patients specifically, depression is 
one of the most common comorbidities with a prevalence 
of 10–57% [6], and is related to a higher risk of acute 
exacerbation, frequent hospitalization, and mortality [24, 
25]. Therefore, early detection of depression followed by 
proper interventions in COPD patients are important to 
control depressive symptoms and clinical prognosis in 
COPD patients [26].
The PHQ-9 is a brief version, composed of nine items, 
of a longer depression scale, the Patient Health Question-
naire (PHQ), that is based on the DSM-IV diagnosis of 
depressive disorders [27]. This brief screening instrument 
can easily be used in primary healthcare centers and is 
considered to have comparable sensitivity and specific-
ity to other depression screening instruments [7]. Many 
studies have been conducted to determine an appro-
priate cut-off value of the PHQ-9 when screening for 
depression [28], with some reporting that a cut-off value 
over 10, which is classified as moderate depression sever-
ity on the scale, is considered to be reliable for screening 
for depressive disorders [29, 30]. However, Lesley et  al. 
reported that PHQ-9 ≥ 5 was the optimal cut-off value 
to detect depression in patients with coronary artery dis-
ease, which was lower than even the recommended cut-
off score [31]. Likewise, Han et  al. also recommended 
that a PHQ-9 score of 5, based on the Korean version, 
was appropriate to detect depression in elderly patients 
[22]. In our study, 76.9% (674/877) of participants were 
elderly patients over 60  years old. Moreover, the preva-
lence of depression in our participants with COPD was 
17.8%, which is similar to other previous studies that also 
defined depressive symptoms based on a PHQ-9 score 
of ≥ 5. Therefore, in this study, we chose this value to 
define the presence of depressive symptoms. While this 
value may be lower than those in previous reports, the 
benefit is that we may be able to detect depressive symp-
toms in COPD patients earlier and initiate the proper 
intervention.
In previous studies, the severity of COPD, living alone, 
respiratory symptoms [10], and lower BMI [32] were sig-
nificantly related to the development of depression in 
patients with COPD. Additionally, Jasmin et  al. found 
that factors including female sex, low socioeconomic sta-
tus, lower FEV1, the degree of dyspnea, smoking, obesity, 
low social support, and loneliness were associated with 
an increase of depression in obstructive lung disease [11]. 
In the current study, female sex, low BMI, living alone, 
being a current smoker, and having a GOLD Stage III/
IV were also significant risk factors for depressive symp-
toms. However, low income, educational attainment, 
and household income were not significantly different 
between patients with COPD comorbid with depression.
COPD is no longer a disease more commonly found 
in males owing to increased tobacco use in females and 
exposure to air pollution [33]. It has been demonstrated 
that the susceptibility to COPD, related risk factors, clini-
cal presentation, comorbidities, and response to treat-
ment differ between males and females [34]. Among 
them, depression and other psychological disorders, 
including anxiety and irritability, are more prevalent in 
females [35]. Therefore, greater effort should be made in 
identifying and managing these conditions [36]. In a sub-
group analysis, we found that there were differences in 
the risk factors of depression in COPD patients by sex, 
indicating that different approaches may be needed to 
Table 1 (continued)
Data are presented as numbers (%) or mean ± SD
A p value of < 0.05 was considered significant (bold) for all analyses
PHQ-9, patient health questionnaire-9; BMI, body mass index; SD, standard deviation; GOLD, global initiative for chronic obstructive lung disease
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predict depression in COPD patients depending on their 
sex.
This study has several limitations. The first is that 
this was a retrospective study based on data from the 
KNHANES, a nationwide survey that evaluated the 
health and nutritional status of the Korean population. 
Hence, it is possible that COPD patients with moderate 
to high severity were not included, as this data included 
the results of healthy patients for medical screening. 
However, our findings could help in detecting depres-
sive symptoms early and prevent disease progression in 
mild COPD patients. Second, we analysed using only 
pre-bronchodilator results because post-bronchodilator 
results were not available in the KNHANES protocol. 
However, the COPD patients with only pre-broncho-
dilator results and no post-bronchodilator results had 
shown fairly similar presentation when compared to 
patients with both pre-bronchodilator and post-broncho-
dilator results [37]. Third, the severity of symptoms and 
the treatment the patients received, aspects that could 
affect the patients’ quality of life and the development 
of depression, were not able to be investigated. Further 
study regarding this point should be undertaken to sup-
port our findings.
Nevertheless, our research also has its strengths, in that 
it shows the risk factors associated with the occurrence 
of depressive symptoms in COPD patients, including a 
difference in risk factors between males and females. Fur-
thermore, we demonstrated that there is an opportunity 
to detect and manage depressive symptoms at an early 
stage by analyzing the data of patients with mild severity 
of COPD, though prospective and large-sample studies 
are needed for validation.
Conclusions
We found that the incidence of depressive symptoms 
was not lower even in patients with mild COPD. How-
ever, female sex was a main risk factor for depressive 
symptoms in adults with COPD. Thus, the risk factors of 
depressive symptoms in COPD patients differed accord-
ing to sex. We suggest that COPD patients found to have 
these risk factors should be kept under close observation 
to prevent depression and exacerbation of disease-related 
symptoms.
Table 2 Results of the relative risk regression analysis for the 
associated factors with depressive symptoms (PHQ‑9 ≥ 5)
RR 95% CI P value
Sex
Male 1.00
Female 2.38 1.55 3.66  < 0.001
Age (years)
40–49 1.00
50–59 0.95 0.45 1.98 0.886
60–69 0.88 0.43 1.80 0.728
≥ 70 0.89 0.42 1.88 0.750
Educational attainment
Elementary school or below 1.00
Middle school 0.73 0.47 1.14 0.167
High school 0.76 0.50 1.15 0.200
College or above 0.80 0.46 1.39 0.426
Equalized household income
Quartile 1 (low) 1.00
Quartile 2 0.79 0.54 1.16 0.234
Quartile 3 0.67 0.42 1.08 0.104
Quartile 4 (high) 0.57 0.33 0.97 0.039
Living status
Living together 1.00
Living alone 1.46 1.08 1.97 0.013
Economic activity
Employed 1.00
Unemployed 1.06 0.78 1.45 0.695
Residential area
Urban 1.00
Rural 0.78 0.59 1.03 0.080
Alcohol consumption status
Never drinker 1.00
Former drinker 1.08 0.72 1.63 0.713
Current drinker 1.09 0.71 1.69 0.688
Smoking status
Never smoker 1.00
Former smoker 1.23 0.75 2.02 0.412
Current smoker 1.70 1.15 2.52 0.008
Chronic medical diseases
None 1.00
One 0.91 0.65 1.28 0.598
Two or more 1.01 0.68 1.51 0.947
BMI
Underweight 1.58 1.00 2.49 0.049
Normal weight 1.00
Overweight 0.75 0.51 1.10 0.145
Obesity 0.82 0.58 1.17 0.275
GOLD stage
Stage 1 1.00
Stage 2 0.99 0.74 1.34 0.957
Stage 3 and 4 1.92 1.19 3.09 0.007
Table 2 (continued)
A p value of < 0.05 was considered significant (bold) for all analyses
PHQ-9, Patient health questionnaire-9; BMI, body mass index; GOLD, global 
initiative for chronic obstructive lung disease; RR, relative risk; CI, confidence 
interval
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Table 3 Results of the relative risk regression analysis for the associated factors with depressive symptoms (PHQ‑9 ≥ 5) stratified by sex
A p value of < 0.05 was considered significant (bold) for all analyses
PHQ-9, patient health questionnaire-9; BMI, body mass index; GOLD, global initiative for chronic obstructive lung disease; RR, relative risk; CI, confidence interval
Male Female
N = 627 N = 250
RR 95% CI P value RR 95% CI P value
Age (years)
40–49 1.00 1.00
50–59 1.10 0.39 3.07 0.861 0.75 0.23 2.42 0.627
60–69 1.26 0.49 3.23 0.634 0.48 0.14 1.66 0.244
≥ 70 0.98 0.36 2.61 0.960 0.76 0.20 2.81 0.677
Educational attainment
Elementary school or below 1.00 1.00
Middle school 0.94 0.50 1.77 0.851 0.50 0.23 1.09 0.080
High school 1.49 0.87 2.55 0.151 0.28 0.11 0.69 0.006
College or above 1.84 0.93 3.63 0.078 0.24 0.07 0.84 0.025
Equalized household income
Quartile 1 (low) 1.00 1.00
Quartile 2 0.50 0.29 0.89 0.017 1.39 0.79 2.44 0.254
Quartile 3 0.53 0.28 0.98 0.041 0.76 0.33 1.74 0.510
Quartile 4 (high) 0.24 0.10 0.57 0.001 1.37 0.69 2.71 0.368
Living status
Living together 1.00 1.00
Living alone 1.97 1.18 3.28 0.009 1.32 0.81 2.16 0.269
Economic activity
Employed 1.00 1.00
Unemployed 0.86 0.54 1.38 0.534 1.36 0.83 2.24 0.223
Residential area
Urban 1.00 1.00
Rural 0.97 0.64 1.46 0.889 0.56 0.36 0.88 0.012
Alcohol consumption status
Never drinker 1.00 1.00
Former drinker 1.71 0.71 4.15 0.234 1.12 0.65 1.93 0.677
Current drinker 1.59 0.67 3.80 0.295 1.06 0.51 2.20 0.874
Smoking status
Never smoker 1.00 1.00
Former smoker 0.91 0.44 1.88 0.805 1.78 0.54 5.91 0.342
Current smoker 1.56 0.76 3.21 0.228 1.51 0.76 2.99 0.233
Chronic medical diseases
None 1.00 1.00
One 1.36 0.84 2.20 0.212 0.64 0.35 1.16 0.138
Two or more 2.04 1.15 3.63 0.015 0.56 0.27 1.15 0.113
BMI
Underweight 3.35 1.16 9.68 0.026 1.41 0.58 3.45 0.445
Normal weight 1.00 1.00
Overweight 0.99 0.58 1.67 0.968 0.66 0.33 1.29 0.219
Obesity 0.89 0.54 1.46 0.640 0.61 0.32 1.13 0.113
GOLD stage
Stage 1 1.00 1.00
Stage 2 0.70 0.45 1.09 0.115 1.37 0.82 2.26 0.225
Stage 3 and 4 1.53 0.78 2.99 0.214 2.50 0.89 7.08 0.083
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